{"analyses":[{"ciLowerLimit":"2.463","ciPctValue":"95","ciUpperLimit":"4.676","groupDescription":"P-value was obtained from Cochran-Mantel-Haenszel (CMH) test stratified by ECOG PS, brain metastases, and prior EGFR TKI treatment. The risk ratio and corresponding 95% CI from the stratified CMH test were also reported.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"Statistical significance: 2-sided at alpha=0.025.","paramType":"Risk Ratio (RR)","paramValue":"3.394","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.7","upperLimit":"72.4","value":"65.3"},{"groupId":"OG001","lowerLimit":"13.9","upperLimit":"26.2","value":"19.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\\<10 millimeter \\[mm\\] short axis). PR: at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. Objective response is based on independent radiology review.","dispersionType":"95% Confidence Interval","groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG000","title":"Crizotinib"},{"description":"Pemetrexed 500 mg/m\\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"FAS included all participants who were randomized to study treatment.","reportingStatus":"POSTED","timeFrame":"Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)","title":"Percentage of Participants With Objective Response (OR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}